Analysts Anticipate Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) to Announce ($0.06) Earnings Per Share

Shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $2.27 for the company and are forecasting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Zomedica Pharmaceuticals Corp (NYSEAMERICAN) an industry rank of 82 out of 256 based on the ratings given to its competitors.

Separately, HC Wainwright restated a “buy” rating on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a research report on Wednesday, June 5th.

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 2.3% in the 4th quarter. BlackRock Inc. now owns 1,767,342 shares of the company’s stock worth $2,173,000 after purchasing an additional 40,244 shares during the period. Rhumbline Advisers raised its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% in the 4th quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock worth $57,000 after purchasing an additional 16,750 shares during the period. Vanguard Group Inc raised its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6.1% in the 3rd quarter. Vanguard Group Inc now owns 145,747 shares of the company’s stock worth $273,000 after purchasing an additional 8,381 shares during the period. Finally, Geode Capital Management LLC raised its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after purchasing an additional 16,065 shares during the period. Hedge funds and other institutional investors own 14.64% of the company’s stock.

ZOM stock traded down $0.02 during mid-day trading on Friday, hitting $0.25. The company had a trading volume of 831,297 shares, compared to its average volume of 420,423. The stock has a market cap of $27.28 million, a P/E ratio of -1.40 and a beta of 0.80. Zomedica Pharmaceuticals Corp has a 12-month low of $0.20 and a 12-month high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.12) EPS for the quarter. On average, research analysts forecast that Zomedica Pharmaceuticals Corp will post -0.26 EPS for the current fiscal year.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Recommended Story: Portfolio Manager

Get a free copy of the Zacks research report on Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.